NCT01767714 - Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

Granulocyte-colony stimulating factor (G-CSF)

10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection

DRUG

Plerixafor

0.24 mg/kg/day subcutaneous injection

DRUG

Placebo

0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection

Trial Locations (16)

100034

Investigational Site Number 156017, Beijing

100044

Investigational Site Number 156001, Beijing

100071

Investigational Site Number 156005, Beijing

100142

Investigational Site Number 156002, Beijing

100730

Investigational Site Number 156003, Beijing

200025

Investigational Site Number 156009, Shanghai

210029

Investigational Site Number 156018, Nanjing

215006

Investigational Site Number 156010, Suzhou

300020

Investigational Site Number 156008, Tianjin

310003

Investigational Site Number 156011, Hangzhou

350001

Investigational Site Number 156016, Fuzhou

400037

Investigational Site Number 156020, Chongqing

430022

Investigational Site Number 156013, Wuhan

450008

Investigational Site Number 156022, Zhengzhou

510060

Investigational Site Number 156021, Guangzhou

710038

Investigational Site Number 156015, Xi'an